Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol
- PMID: 25416201
- DOI: 10.1007/s00404-014-3552-6
Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol
Abstract
Purpose: To evaluate the effects of D-Chiro-Inositol in women affected by polycystic ovary syndrome (PCOS).
Methods: We enrolled 48 patients, with homogeneous bio-physical characteristics, affected by PCOS and menstrual irregularities. These patients underwent treatment with 1 gr of D-Chiro-Inositol/die plus 400 mcg of Folic Acid/die orally for 6 months. We analyzed pre-treatment and post-treatment BMI, Systolic and Diastolic blood pressure, Ferriman-Gallwey score, Cremoncini score, serum LH, LH/FSH ratio, total and free testosterone, DHEA-S, Δ-4-androstenedione, SHBG, prolactin, glucose/IRI ratio, HOMA index, and resumption of regular menstrual cycles.
Results: We evidenced a statistically significant reduction of systolic blood pressure, Ferriman-Gallwey score, LH, LH/FSH ratio, total Testosterone, free Testosterone, ∆-4-Androstenedione, Prolactin, and HOMA Index; in the same patients, we noticed a statistically significant increase of SHBG and Glycemia/IRI ratio. Moreover, we observed statistically significant (62.5%; p < 0.05) post-treatment menstrual cycle regularization.
Conclusions: D-Chiro-Inositol is effective in improving ovarian function and metabolism of patients affected by PCOS.
Comment in
-
"Empiric" inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects.Arch Gynecol Obstet. 2015 May;291(5):955-7. doi: 10.1007/s00404-015-3662-9. Epub 2015 Feb 17. Arch Gynecol Obstet. 2015. PMID: 25687659 No abstract available.
-
Authors' reply to: "Empiric" inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects.Arch Gynecol Obstet. 2015 May;291(5):959-60. doi: 10.1007/s00404-015-3663-8. Arch Gynecol Obstet. 2015. PMID: 25687660 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
